Quantum Pharma PLC Appointment of Chief Financial Officer (3168R)
08 December 2016 - 7:45PM
UK Regulatory
TIDMQP.
RNS Number : 3168R
Quantum Pharma PLC
08 December 2016
For immediate release 8 December 2016
Quantum Pharma Plc
('Quantum' or the 'Group')
Appointment of Chief Financial Officer
Quantum Pharma Plc (AIM: QP.), the service-led niche
pharmaceutical developer, manufacturer and supplier to the health
and care sectors, is pleased to announce the appointment of Gerard
(Ged) Murray to the Board as Chief Financial Officer (CFO) with
effect from 23 January 2017. Chris Rigg, Quantum's CEO, will
continue in his joint role as CEO and CFO until that date.
Gerard brings with him a wealth of experience, having been
finance director for a number of publicly quoted companies. He
qualified as a Chartered Accountant with Arthur Andersen and spent
over ten years serving as CFO and then CEO of Reg Vardy plc before
joining Northgate plc as group finance director for a five year
period. Both of these quoted companies experienced considerable
growth during the periods that he served on their respective
boards. Gerard also has sector experience from a period as group
finance director of Immunodiagnostic Systems Holdings PLC. More
recently he led the sale of Benfield Motor Group, a family owned
motor retailer for GBP87.5 million to Lookers plc in September 2015
before joining Ardent Hire Solutions Limited, a private equity
backed plant hire business, where he has been the CFO since April
2016.
Commenting on the appointment, Chris Rigg, CEO and CFO of
Quantum Pharma Plc, said: "I am delighted that Ged is joining
Quantum as our new CFO. He has an excellent track record and
reputation, having worked as finance director for a number of
well-known and respected public companies and will further
strengthen and complement the Board. The Board joins me in
welcoming him to Quantum and we look forward to benefiting from his
considerable knowledge and experience in helping drive our focused
and simplified business forward and generating value for our
shareholders."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Gerard Thomas Murray,
age 53 years, has been a director of the following companies during
the five years preceding the date of this announcement:
Current directorships Past directorships
---------------------- --------------------------------------
Wren Topco Limited Addison Motor Company (02/09/2015)
Transflex Vehicle IDS plc (30/11/2012)
Rental Limited
One Call Hire Capital Sonik Sports Limited (12/09/2012)
Limited
Fork Rent Limited Peter Vardy Holdings Limited
(30/05/2012)
One Call Hire Limited Vardy Property Group Limited
(02/04/2012)
One Call Tool Hire Addison TPS Limited (02/09/2015)
Limited
Ardent Hire Solutions The King's School Tynemouth
Limited Limited (02/09/2015)
Wren EBT Limited J.M Sloan & Company Limited
(02/09/2015)
Wren Buyerco Limited Squires Capital Limited (02/09/2015)
Wren Rollco Limited Benfield Motor Group Limited
(02/09/2015)
Benfield Pension Motor Group
Limited (02/09/2015)
Immunodiagnostics Systems
Holdings Public Limited Company
(30/11/2012)
ST Ebba Capital Limited (02/09/2015)
J M Sloan & Company (Car Hire)
Limited (02/09/2015)
Addison Motors Limited (02/09/2015)
Rosedale Finance & Leasing
Limited (02/09/2015)
Harpers Carlisle limited (02/09/2015)
Colebrook & Burgess Limited
(02/09/2015)
Colebrook & Burgess (Teeside)
Limited (02/09/2015)
Colebrook & Burgess (North
Shields) Limited (02/09/2015)
Colebrook & Burgess (Wallsend)
Limited (02/09/2015)
Colebrook & Burgess Holdings
Limited (02/09/2015)
Immunodiagnostics Systems
Limited (30/11/2012)
The Great North Bakery Limited
(02/04/2012)
Peter Vardy Limited (30/05/2012)
Vardy Family Office Limited
(02/04/2012)
Vardy Ventures Limited (02/04/2012)
Vardy Property (Teesside)
Limited (02/04/2012)
Vardy Property Aberdeen Limited
(02/04/2012)
Carolina Court (VPG) Limited
(02/04/2012)
Macleods of Perth Limited
(30/05/2014)
Vardy Property 100 Limited
(02/04/2012)
Vardy Properties (02/04/2012)
Elswick (vpg) limited (02/04/2012)
There is no further information to be disclosed pursuant to Rule
17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
- Ends -
For further information:
Quantum Pharma Plc
Ian Johnson, Chairman Tel: +44 (0) 1207
Chris Rigg, CEO and CFO 279 404
Craig Swinhoe, Group Strategic www.quantumpharmaplc.com
Projects Director and Company
Secretary
N+1 Singer (NOMAD and Broker) Tel: +44 (0) 20
7496 3000
Sandy Fraser / Nick Owen / www.n1singer.com
James White
Media enquiries:
Buchanan
Henry Harrison-Topham / Sophie Tel: +44 (0) 20
Cowles / Steph Watson 7466 5000
quantumpharma@buchanan.uk.com www.buchanan.uk.com
Notes to Editors
Quantum Pharma Plc is a service-led, niche pharmaceutical
developer, manufacturer and supplier to the retail pharmacy,
pharmaceutical wholesaler, hospital, homecare and care home
markets. Quantum Pharma operates through three divisions: Specials,
Niche Pharmaceuticals and Medication Adherence, offering a
portfolio of innovative and complementary products and
services.
Specials comprises three business units (Quantum Pharmaceutical,
UL Medicines and Quantum Aseptics Services). This division
manufactures, procures and supplies bespoke specials; batch made
specials; aseptically prepared sterile intravenous medicines;
imported medicines and special obtain products in response to a
request from a prescriber for a bespoke medicine or special product
to optimise patient treatment. The division offers an unrivalled
and constantly expanding range of products. It has a
customer-focused, service-driven business model, which provides
shorter lead times than any of its competitors.
Niche Pharmaceuticals comprises three business units (Colonis,
Lamda and PERN Consumer Products). This division is a product
development and commercialisation business focusing on taking niche
drugs through the regulatory pathway to achieve regulated status
(licensed product or medical device). The division uses the
excellent visibility of trends in the UK pharmacy and hospital
markets gained through our Specials and Medication Adherence
divisions, to allow early identification of the market opportunity
to take products from unlicensed to licensed status. The division
has a growing portfolio and pipeline of products that fit this
unlicensed to licensed pathway, as well as complementary generic,
generic plus or medical devices intended to meet unmet patient
needs across a number of therapeutic areas.
Medication Adherence comprises two business units (Biodose(R)
and Biodose Services(R)). This division provides products and
services to enhance the likelihood of a patient adhering to a
medication regime, patient-focused homecare services and services
to pharmaceutical companies. It owns Biodose(R), the only
medication delivery system on the market that accommodates both
liquid and solid doses. Biodose Connect(TM) takes patient safety
and adherence to the next level by enabling remote monitoring of
adherence to medication regimes. The division also operates a range
of specialist patient-focused homecare services to the NHS, private
clinics and pharmaceutical companies and provides the Group with
exposure to the homecare and supported living sectors of the care
pathway, complementing the focus of the remainder of the Group.
For further information, please visit
www.quantumpharmaplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGIBDDRXGBGLI
(END) Dow Jones Newswires
December 08, 2016 03:45 ET (08:45 GMT)
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From Apr 2024 to May 2024
Quantum Phar. (LSE:QP.)
Historical Stock Chart
From May 2023 to May 2024